Table 2.
Changes in body mass index and selected serum parameters during the trial.
| Placebo | Pioglitazone | Interaction | |||||
|---|---|---|---|---|---|---|---|
| Baseline | 24 Weeks | P | Baseline | 24 Weeks | P | P | |
| BMI, kg/m2 | 34.9 (31.0 to 38.7) | 34.0 (30.1 to 37.9) | 0.18 | 35.1 (31.1 to 39.0) | 35.8 (31.9 to 39.8) | 0.19 | 0.07 |
| Serum | |||||||
| Insulin, mU/La | 9.0 (6.2 to 13.2) | 12.0 (7.9 to 18.4) | 0.19 | 11.8 (8.0 to 17.3) | 8.1 (5.5 to 11.9) | 0.06 | 0.03 |
| NEFFA, mEq/L | 0.52 (0.43 to 0.62) | 0.57 (0.44 to 0.70) | 0.48 | 0.61 (0.51 to 0.70) | 0.56 (0.46 to 0.66) | 0.45 | 0.31 |
| Glucose, mmoles/L | 5.4 (4.7 to 6.1) | 5.4 (4.8 to 6.0) | 0.99 | 6.4 (5.6 to 7.3) | 5.4 (4.9 to 6.0) | 0.01 | 0.09 |
| Phosphorus, mmoles/L | 1.13 (1.06 to 1.20) | 1.09 (1.01 to 1.18) | 0.30 | 1.12 (1.05 to 1.19) | 1.10 (1.02 to 1.18) | 0.45 | 0.77 |
| Magnesium, mmoles/L | 0.89 (0.85 to 0.93) | 0.87 (0.83 to 0.91) | 0.30 | 0.85 (0.81 to 0.89) | 0.82 (0.78 to 0.85) | 0.05 | 0.56 |
| Alkaline Phosphatase, μkat/L | 1.30 (1.12 to 1.48) | 1.17 (1.00 to 1.33) | 0.004 | 1.24 (1.06 to 1.42) | 1.13 (0.98 to 1.29) | 0.009 | 0.63 |
| AST, μkat/L | 0.36 (0.30 to 0.43) | 0.38 (0.30 to 0.46) | 0.67 | 0.39 (0.32 to 0.46) | 0.33 (0.25 to 0.40) | 0.07 | 0.13 |
| Cholesterol, mmoles/La | 5.26 (4.70 to 5.90) | 5.07 (4.45 to 5.79) | 0.36 | 5.25 (4.69 to 5.87) | 4.99 (4.40 to 5.65) | 0.15 | 0.80 |
a
Data presented as Least Square Means or geometric means (95% confidence intervals). Interaction P value corresponds to the treatment and visit interaction for comparison between placebo and pioglitazone groups